New team members and structure will drive continued growth.
KING OF PRUSSIA, PA – February 18, 2015 – Genomind, a pharmacogenetic testing laboratory specializing in personalized medicine in the field of psychiatry, today announced the addition of the following executive team members: Shelley Glick, Vice President, Managed Care; Jeff Wisotzkey, Lab Director and Vice President, Molecular Pathology; Kristina Habermann, Vice President, Marketing and Corporate Communications; and Mike Adriani, Senior Vice President, Information Technology. Genomind also has promoted Rob Gibbs to the position of Chief Commercial Officer. These additions and changes bring further robust leadership experience both inside and outside the healthcare and biotech industries to Genomind. Michael Koffler, Genomind’s President and CEO, said “We are delighted to welcome these accomplished executives to our growing company, and to announce Rob’s promotion. The continued expansion of our leadership team is reflective of the success we have had in helping tens of thousands of patients with mental illness.”
Ms. Glick is responsible for all collaboration between Genomind, payers, and payer stakeholders. In this role, Ms. Glick leads all managed care initiatives for Genomind related to reimbursement, billing policies, and carrier contracting for Genomind’s technology. Ms. Glick brings over 13 years of experience in molecular diagnostics and the medical device industry with a focus on managed care, payer relations, and health economics.
Dr. Wisotzkey is responsible for all aspects of laboratory operations at Genomind. Dr. Wisotzkey has extensive experience and expertise in clinical molecular diagnostic testing in the fields of genetics, oncology and infectious diseases. Prior to joining Genomind, he served for ten years as the Director, Molecular Pathology and Technical Director of Laboratory Operations at the Central Pennsylvania Alliance Laboratory in York, PA.
Ms. Habermann is responsible for all marketing and external corporate communications at Genomind, including market research/product development, healthcare provider education, social media/web development, conference strategy, public relations, direct marketing, advertising and overall brand awareness. Ms. Habermann brings over 17 years of experience in the field of genetics ranging from genetic counseling to sales and marketing. Prior to joining Genomind, Ms. Habermann worked in product management at PerkinElmer’s Diagnostics Division, focusing on the development and marketing of prenatal and pediatric testing services. Ms. Habermann received an M.S. in Genetic Counseling from the Mount Sinai School of Medicine and is a board certified genetic counselor.
Mr. Adriani is responsible for all aspects of Genomind’s information technology, services and operations, leading the IT team to deliver solutions that enable business strategies. Mr. Adriani has over eighteen years of experience in information technology, specializing in medical diagnostic IT services. As Vice President of IT for PLUS Diagnostics, he implemented and architected numerous applications, including: data-warehousing, specimen tracking systems, medical diagnostics report delivery systems, and customer relationship management systems.
Genomind also announces the promotion of Rob Gibbs to Chief Commercial Officer. This newly created position represents the maturation of the pharmacogenetics market in psychiatry and Genomind’s leading position in that field. In this role, Mr. Gibbs will lead all commercial aspects of Genomind’s business including sales, marketing, business operations, and customer service. Mr. Gibbs has spent his entire career in healthcare, holding leadership positions at Cigna and Medecision in Sales, Marketing, Finance and Operations for over 15 years.
Genomind is a pharmacogenetic testing laboratory specializing in personalized medicine in the field of psychiatry, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
About the Genecept™ Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product and utilizes a proprietary panel of biomarker tests, providing an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, PTSD, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/the-science-behind-the-test/
For more information, contact:
Marketing Manager, Genomind